Alan J. Garber
#152,222
Most Influential Person Now
Alan J. Garber's AcademicInfluence.com Rankings
Alan J. Garberphilosophy Degrees
Philosophy
#8462
World Rank
#11851
Historical Rank
Logic
#5493
World Rank
#6898
Historical Rank
Download Badge
Economics Philosophy
Alan J. Garber's Degrees
- PhD Economics Stanford University
Why Is Alan J. Garber Influential?
(Suggest an Edit or Addition)Alan J. Garber's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- K/DOQI clinical practice guidelines for chronic kidney disease (2002) (8858)
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial (2009) (1055)
- Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. (2009) (969)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY. (2016) (869)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE. (2017) (800)
- American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. (2015) (607)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016) (606)
- Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. (2005) (582)
- American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. (2011) (579)
- Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. (1997) (483)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. (2018) (478)
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone (2009) (429)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. (2017) (416)
- AACE comprehensive diabetes management algorithm 2013. (2013) (401)
- The role of adrenergic mechanisms in the substrate and hormonal response to insulin-induced hypoglycemia in man. (1976) (383)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. (2019) (326)
- Metabolic syndrome. (2014) (322)
- Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial (2012) (315)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. (2020) (312)
- Attainment of glycaemic goals in type 2 diabetes with once‐, twice‐, or thrice‐daily dosing with biphasic insulin aspart 70/30 (The 1‐2‐3 study) (2006) (299)
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists (2011) (296)
- Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo‐controlled study * (2007) (289)
- American College of Endocrinology position statement on inpatient diabetes and metabolic control. (2004) (278)
- Weight loss with liraglutide, a once‐daily human glucagon‐like peptide‐1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue (2009) (269)
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial (2011) (249)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. (2016) (246)
- AACE/ACE comprehensive diabetes management algorithm 2015. (2015) (243)
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea * (2008) (239)
- American College of Endocrinology position statement on inpatient diabetes and metabolic control. (2004) (234)
- Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. (2008) (229)
- American Association of Clinical Endocrinologists' comprehensive diabetes management algorithm 2013 consensus statement--executive summary. (2013) (218)
- Hepatic ketogenesis and gluconeogenesis in humans. (1974) (201)
- Alanine and glutamine synthesis and release from skeletal muscle. I. Glycolysis and amino acid release. (1976) (178)
- Phosphoenolpyruvate carboxykinase. I. Its role in gluconeogenesis. (1972) (173)
- Alanine and glutamine synthesis and release from skeletal muscle. II. The precursor role of amino acids in alanine and glutamine synthesis. (1976) (171)
- American association of clinical endocrinologists and american college of endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease. (2014) (166)
- Alanine and glutamine synthesis and release from skeletal muscle. IV. beta-Adrenergic inhibition of amino acid release. (1976) (153)
- Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria (1996) (151)
- Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center (2002) (137)
- Effects of parathyroid hormone on skeletal muscle protein and amino acid metabolism in the rat. (1983) (134)
- Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials. (2011) (132)
- American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine. (2012) (127)
- Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes (2002) (125)
- Clinical, biochemical, and neuropathologic findings following transplantation of adrenal medulla to the caudate nucleus for treatment of Parkinson's disease (1989) (121)
- Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats. (2002) (116)
- Hypoglycemia in Compensated Chronic Renal Insufficiency: Substrate Limitation of Gluconeogenesis (1974) (111)
- Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes. (2003) (109)
- Obesity and type 2 diabetes: which patients are at risk? (2012) (99)
- Premixed insulin treatment for type 2 diabetes: analogue or human? (2007) (93)
- Initial treatment with rosiglitazone/metformin fixed‐dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes (2006) (92)
- The clinical approach to the detection of lipodystrophy - an AACE consensus statement. (2013) (90)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARYComplete Appendix to Guidelines available at http://journals.aace.com. (2017) (89)
- Abnormal carbohydrate metabolism in chronic renal failure. The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal. (1978) (89)
- American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Practice Guidelines--2010 update. (2010) (87)
- Diabetes and cancer--an AACE/ACE consensus statement. (2013) (79)
- Diabetes and vascular disease (2000) (78)
- American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. (2011) (78)
- Consensus Development Conference on the Diagnosis and Management of Nephropathy in Patients with Diabetes Mellitus (1994) (78)
- Metformin‐glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy (2006) (77)
- Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center (2004) (77)
- The regulation of gluconeogenesis in mammalian liver. The role of mitochondrial phosphoenolpyruvate carboxykinase. (1973) (73)
- Treat-to-target trials: uses, interpretation and review of concepts (2013) (72)
- Incretin Effects on β-Cell Function, Replication, and Mass (2011) (72)
- Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary. (2020) (71)
- Propranolol does not prevent thyroid storm. (1977) (69)
- Novel GLP-1 receptor agonists for diabetes (2012) (67)
- Skeletal muscle protein and amino acid metabolism in experimental chronic uremia in the rat: accelerated alanine and glutamine formation and release. (1978) (62)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY--CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN--2015--EXECUTIVE SUMMARY. (2015) (61)
- Alanine and glutamine synthesis and release from skeletal muscle. III. Dietary and hormonal regulation. (1976) (59)
- Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes (2010) (58)
- Basal insulin or premix analogue therapy in type 2 diabetes patients. (2007) (57)
- DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. (2018) (54)
- Reduced Risk of Confirmed Hypoglycemia (Plasma Glucose <2.3 mmol/L) with Insulin Degludec vs. Insulin Glargine in Patients with Type 2 Diabetes: A Meta-analysis of 5 Randomized Trials (2013) (54)
- Attenuating CV risk factors in patients with diabetes: clinical evidence to clinical practice (2002) (52)
- Vascular disease and lipids in diabetes. (1998) (52)
- Lower Risk of Hypoglycemia with Insulin Detemir than with Neutral Protamine Hagedorn Insulin in Older Persons with Type 2 Diabetes: A Pooled Analysis of Phase III Trials (2007) (52)
- Premixed Insulin Analogues for the Treatment of Diabetes Mellitus (2012) (52)
- American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. (2010) (52)
- Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial (2012) (51)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITYEXECUTIVE SUMMARYComplete Guidelines available at https://www.aace.com/publications/guidelines. (2016) (49)
- Glucagon-stimulable adenylyl cyclase in rat liver. The impact of streptozotocin-induced diabetes mellitus. (1984) (48)
- The metabolic syndrome: a call to action. (2006) (47)
- GLP-1R agonist therapy for diabetes: benefits and potential risks (2013) (45)
- The interrelationships of the various pathways forming gluconeogenic precursors in guinea pig liver mitochondria. (1971) (44)
- COMPARISON OF THE LONG-TERM EFFECTS OF LIRAGLUTIDE AND GLIMEPIRIDE MONOTHERAPY ON BONE MINERAL DENSITY IN PATIENTS WITH TYPE 2 DIABETES. (2016) (43)
- Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents (2013) (43)
- Incretin-based therapies in the management of type 2 diabetes: rationale and reality in a managed care setting. (2010) (41)
- American association of clinical endocrinologists and american college of endocrinology consensus conference on obesity: building an evidence base for comprehensive action. (2014) (41)
- Bioactivity of instant glucose. Failure of absorption through oral mucosa. (1978) (41)
- Sulfonamide-induced hypoglycemia in chronic renal failure. (1983) (38)
- Improvement in glycaemic control with rosiglitazone/metformin fixed‐dose combination therapy in patients with type 2 diabetes with very poor glycaemic control (2006) (38)
- Benefits of combination therapy of insulin and oral hypoglycemic agents. (2003) (36)
- Insulin degludec improves long‐term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal‐bolus insulin therapy (2015) (34)
- Role of insulin signaling in maintaining energy homeostasis. (2008) (34)
- Attenuating cardiovascular risk factors in patients with type 2 diabetes. (2000) (34)
- Detection and Management of Lipid Disorders in Diabetic Patients: A commentary for clinicians (1992) (33)
- American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control. (2006) (33)
- Non‐glycaemic effects mediated via GLP‐1 receptor agonists and the potential for exploiting these for therapeutic benefit: focus on liraglutide (2012) (33)
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY 2018 POSITION STATEMENT ON INTEGRATION OF INSULIN PUMPS AND CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH DIABETES MELLITUS. (2018) (33)
- Serotonergic and adrenergic regulation of skeletal muscle metabolism in the rat. II. The use of [125I]iodolysergic acid diethylamide and [125I]iodopindolol as probes of sarcolemmal receptor function and specificity. (1983) (32)
- Renal failure after small intestinal bypass for obesity. (1975) (31)
- Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes (2012) (31)
- The impact of streptozotocin-induced diabetes mellitus on cyclic nucleotide regulation of skeletal muscle amino acid metabolism in the rat. (1980) (31)
- The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendations. (2013) (31)
- Phosphoenolpyruvate synthesis and release by mitochondria from guinea pig liver. (1969) (30)
- Will the next generation of basal insulins offer clinical advantages? (2014) (30)
- CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. (2015) (30)
- Monoiodoglucagon: synthesis, purification by high pressure liquid chromatography, and characteristics as a receptor probe. (1983) (29)
- Regulation of phosphoenolpyruvate metabolism in mitochondria from guinea pig liver. (1970) (29)
- American Association of Clinical Endocrinologists and American College of Endocrinology Protocol for Standardized Production of Clinical Practice Guidelines, Algorithms, and Checklists--2014 Update and the AACe G4G Program. (2014) (28)
- The Control of Phosphoenolpyruvate Formation by Rabbit Liver Mitochondria THE RELATIONSHIP BETWEEN PHOSPHOENOLPYRUVATE, MALATE, AND ASPARTATE FORMATION AND THE REGULATION OF INTRAMITOCHONDRIAL OXALACETATE (1971) (27)
- The effects of cycloheximide on energy transfer in rat and guinea pig liver mitochondria. (1973) (27)
- Incretin therapy--present and future. (2011) (26)
- IN RESPONSE TO AUTHORS' RESPONSE TO KARL Z. NADOLSKY, DO, RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY. (2018) (25)
- The regulation of skeletal muscle alanine and glutamine formation and release in experimental chronic uremia in the rat: subsensitivity of adenylate cyclase and amino acid release to epinephrine and serotonin. (1978) (25)
- Once-daily saxagliptin added to metformin provides sustained glycaemic control and is well tolerated over 102 weeks in patients with type 2 diabetes (2009) (25)
- Influence of initial hyperglycaemia, weight and age on the blood glucose lowering efficacy and incidence of hypoglycaemic symptoms with a single‐tablet metformin–glibenclamide therapy (Glucovance®) in type 2 diabetes (2003) (25)
- The Regulation of Gluconeogenesis in Mammalian Liver (1973) (25)
- AACE Comprehensive Diabetes Management Algorithm 2013. Endocrine Practice. (2013) (24)
- Update: vildagliptin for the treatment of Type 2 diabetes (2008) (23)
- Skeletal muscle protein and amino acid metabolism in hereditary mouse muscular dystrophy. Accelerated protein turnover and increased alanine and glutamine formation and release. (1980) (23)
- Hypoglycaemia: a therapeutic concern in type 2 diabetes (2012) (22)
- Treatment of dyslipidemia in diabetes. (2001) (22)
- Inhibition of serotonin of amino acid release and protein degradation in skeletal muscle. (1977) (20)
- Postprandial dysmetabolism and the heart. (2012) (20)
- Durability of efficacy and long-term safety profile of glyburide/metformin tablets in patients with type 2 diabetes mellitus: an open-label extension study. (2002) (20)
- The metabolic syndrome. (2004) (20)
- The effect of cycloheximide on the interaction between mitochondrial respiration and gluconeogenesis in guinea pig and rat liver. (1973) (20)
- Benztropine in the treatment of venlafaxine-induced sweating. (1997) (19)
- Using dose–response characteristics of therapeutic agents for treatment decisions in type 2 diabetes (2000) (19)
- Proceedings from the American Association of Clinical Endocrinologists and American College of Endocrinology consensus conference on glucose monitoring. (2015) (19)
- What is the best treatment for prediabetes? (2009) (17)
- Clinical and Angiographic Risk Stratification and Differential Impact on Treatment Outcomes in the Bypass Angioplasty Revascularization Investigation 2 Diabetes ( BARI 2 D ) Trial (2012) (17)
- Phosphoenolpyruvate carboxykinase. II. Hormonal controls. (1973) (17)
- Propranolol for thyroid storm. (1977) (17)
- A Plethora of GLP-1 Agonists: Decisions About What to Use and When (2016) (17)
- Regulation of oxalacetate metabolism in liver mitochondria. Evidence for nicotinamide adenine dinucleotide-malate dehydrogenase equilibrium and the role of phosphoenolpyruvate carboxykinase in the control of oxalacetate metabolism in intact guinea pig and rat liver mitochondria. (1973) (17)
- Glucagon-stimulable adenylyl cyclase in rat liver. Effects of chronic uremia and intermittent glucagon administration. (1984) (16)
- Pharmacologic modifications of hormones to improve their therapeutic potential for diabetes management (2005) (16)
- Advancing the treatment of people with mental illness: a call to action in the management of metabolic issues. (2005) (15)
- Point: Inpatient glucose management: the emperor finally has clothes. (2005) (15)
- THE SIGNIFICANCE OF MITOCHONDRIAL PHOSPHOENOLPYRUVATE FORMATION IN THE REGULATION OF GLUCONEOGENESIS IN GUINEA PIG LIVER (1972) (15)
- Cholinergic stimulation of skeletal muscle alanine and glutamine formation and release. Evidence for mediation by a nicotinic cholinergic receptor and guanosine 3':5'-monophosphate. (1978) (15)
- Glutamine Metabolism in Skeletal Muscle (1980) (14)
- Cardiovascular disease and diabetes: modifying risk factors other than glucose control. (2001) (14)
- An overview of incretin clinical trials. (2008) (14)
- Glucagon‐like peptide‐1‐based therapies: new developments and emerging data (2008) (14)
- Insulin intensification strategies in type 2 diabetes: when one injection is no longer sufficient (2009) (14)
- Current standards of care for inpatient glycemic management and metabolic control: is it time for definite standards and targets? (2004) (13)
- The importance of titrating starting insulin regimens in patients with type 2 diabetes (2009) (12)
- Adrenergic and serotonergic regulation of skeletal muscle metabolism in rat. I. The effects of adrenergic and serotonergic antagonists on the regulation of muscle amino acid release, glycogenolysis, and cyclic nucleotide levels. (1983) (12)
- Metformin and other biguanides: pharmacology and therapeutic usage (2004) (12)
- Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. (2001) (12)
- Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents. (2016) (12)
- Metformin: mechanisms of antihyperglycemic action, other pharmacodynamic properties, and safety perspectives. (1997) (11)
- Skeletal muscle amino acid metabolism in chronic uremia. (1980) (11)
- Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes. (1993) (11)
- Novel Incretin-Based Agents and Practical Regimens to Meet Needs and Treatment Goals of Patients With Type 2 Diabetes Mellitus (2011) (11)
- Magnesium utilization survey in selected patients with diabetes. (1996) (11)
- Impact of hemodialysis on the abnormal glucose and alanine kinetics of chronic azotemia. (1979) (10)
- Methods to enhance delivery of prandial insulin and basal‐prandial insulin (2013) (10)
- The effect of diet upon carbohydrate metabolism, insulin resistance, and blood pressure in congenital total lipoatrophic diabetes. (1980) (9)
- ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES. (2015) (9)
- Synthesis, purification by HPLC and characterization of monoiodoglucagon labeled with carrier free 125I: use as glucagon receptor probe. (1983) (9)
- Skeletal muscle protein and amino acid metabolism in hereditary mouse muscular dystrophy. The role of disordered cyclic nucleotide metabolism in the accelerated alanine and glutamine formation and release. (1980) (8)
- Cardiovascular complications of diabetes: prevention and management. (2003) (8)
- The reduction of body weight with liraglutide, a once-daily human GLP-I analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat (2008) (8)
- Metformin/glyburide tablets as first-line treatment in type 2 diabetes: Distribution of HbA1c response (2000) (7)
- Restaging insulin therapy for patients with type 2 diabetes (2009) (7)
- Metformin and vascular protection: a diabetologist's view. (2003) (7)
- Sarcoplasmic reticulum: a potential internal cyclic AMP effector site and beta-adrenergic receptor. (1978) (7)
- Diabetes, Type 2 (2014) (7)
- Insulin resistance syndrome. A review. (2005) (7)
- Combined Pharmacologic/Nonpharmacologic Intervention in Individuals at High Risk of Developing Type 2 Diabetes (2009) (6)
- Effective treatment of hypertension in patients with diabetes mellitus (1992) (6)
- The importance of incretin therapies for managing type 2 diabetes. (2014) (6)
- Managing cardiac disease in patients with diabetes mellitus. (1983) (6)
- Treatment of diabetes mellitus: the urgent need for multifactorial interventions. (2014) (6)
- Current issues in GLP-1 receptor agonist therapy for type 2 diabetes. (2012) (6)
- Implications of cardiovascular risk in patients with type 2 diabetes who have abnormal lipid profiles: is lower enough? (2000) (6)
- Impact of transfer from animal-source insulins to biosynthetic human insulin (rDNA E coli) in patients with diabetes mellitus. (1991) (6)
- American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia (2018) (6)
- Hypertension and Lipid Management in Prediabetic States (2011) (5)
- GLP-1 receptor agonists: why is once weekly inferior to once daily? (2014) (5)
- Cholinergic stimulation of alanine and glutamine formation and release from skeletal muscle. (1978) (5)
- Adrenergic and serotonergic regulation of skeletal muscle metabolism in the rat: specificity of the serotonin- and isoproterenol-stimulable adenylyl cyclase in sarcolemma (1986) (5)
- Effect of premixed nph and regular insulin on glucose control and health-related quality of life in patients with type 2 diabetes mellitus. (1997) (5)
- Diabetes and heart disease: a new strategy for managing lipid disorders. (1993) (4)
- The effect of hemodialysis on levels of cyclic nucleotide-associated hormones in patients with chronic renal failure. (1980) (4)
- Lower A1c targets in type 2 diabetes and increased mortality: causal or casual? (2013) (4)
- Lessons in initiating insulin in clinical practice. (2008) (4)
- AACE/ACE POSITION STATEMENT ON THE USE OF FOLLOW-ON BIOLOGICS AND BIOSIMILARS FOR ENDOCRINE DISEASES. (2017) (4)
- Assessing the role of biphasic insulin aspart 30 as an effective and tolerable front-line therapy for type 2 diabetes. (2005) (4)
- Incidence of reported gastrointestinal and hypoglycemic symptoms with metformin/glyburide tablets as first-line therapy in type 2 diabetes (2000) (3)
- Current challenges in type 2 diabetes (2012) (3)
- Diabetes and atherosclerosis: mechanisms and management. (1998) (3)
- Lifestyle Interventions for Patients with Type 2 Diabetes and Comorbid Kidney Disease (2013) (2)
- ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES. (2018) (2)
- Diabetic dyslipidemia and the heart. (2006) (2)
- New standards to reduce morbidity and mortality in hospitalized patients with diabetes. (2006) (2)
- Strategies for Better Diabetes Control in the US (2012) (2)
- Insulin degludec is superior to sitagliptin in improving glycaemic control in insulin-naïve patients with type 2 diabetes (2013) (2)
- ACE Inpatient Diabetes and Metabolic Control Consensus Conference - INTRODUCTION (2004) (2)
- Substrate and hormonal responses to hypoglycemia in man (1975) (2)
- Diabetic neuropathy and sexual dysfunction (1998) (2)
- Hyporeninemic hypoaldosteronism. New associations. (1985) (2)
- [125I]iodopindolol: a new beta adrenergic receptor probe. (1981) (2)
- Reducing the risk of stroke through appropriate targets and treatments. (2007) (2)
- Availability of soluble insulin in mixed preparations of crystalline and ultralente biosynthetic human insulin. (1991) (2)
- Obesity management: applying clinical trial data to clinical care. (2014) (1)
- Prevention and treatment of diabetic nephropathy: role of angiotensin-converting enzyme inhibitors. (1996) (1)
- Emerging incretin (glucagon‐like peptide‐1)‐derived therapies for type 2 diabetes (2008) (1)
- Clinical perspectives on type 2 diabetes in North America. (1995) (1)
- Benefits and risks of combination lipid-lowering therapy for combined hyperlipidemias (1997) (1)
- Dyslipidemia as a risk factor for coronary disease in patients with diabetes. (1997) (1)
- Building a solid foundation in diabetes: the nuts and bolts of insulin therapy. (2012) (1)
- Progression from basal to pre-mixed or rapid-acting insulin - Options for intensification and the use of pumps (2009) (1)
- Pathogenesis of Type 2 Diabetes Mellitus 787 (2004) (1)
- Response to Dr. Matz (1993) (0)
- Meal-time glucose control: the role of oral drugs (2004) (0)
- In Response (2017) (0)
- Rebuttal by Dr Garber (2003) (0)
- Liraglutide achieved greater weight reduction and improved glycaemic control compared with sitagliptin following one-year treatment when both are used in combination with metformin (2011) (0)
- Vitamin D and prevention of diabetes: is lifelong endogenous vitamin D needed? (2014) (0)
- Cardiovascular risk and diabetes mellitus management: diagnosis and treatment in special patient populations. Introduction. (2005) (0)
- Point : Inpatient Glucose Management (2005) (0)
- Robert Charles Turner (1999) (0)
- Efficacy of Instant Glucose-Reply (1979) (0)
- Insulin Resistance and Lipoproteins in Hypertriglyceridemia: Effects of Hypolipidemic Drug Treatment (1996) (0)
- Lower Rates in Overall and Nocturnal Hypoglycemia of Insulin Degludec vs. Insulin Glargine with Treatment Intensification in T2DM in Moderately Good Control (A1c 7.5–8.5%) at Baseline: A Meta-Analysis (2012) (0)
- Atherosclerosis in Type 1 Diabetes (2003) (0)
- Insulin Degludec is Superior to Sitagliptin in Improving Glycemic Control in Insulin-naïve Patients with Type 2 Diabetes (2012) (0)
- In Response (2010) (0)
- Vildagliptin: A Viewpoint by Alan J. Garber (2006) (0)
- Standards of care for diabetes management reduce complications. (1996) (0)
- Choline&c Stimulation of Skeletal Muscle Alanine and Glutamine Formation and Release (2012) (0)
- Plasma norepinephrine and epinephrine determined by a sensitive, simplified isotope derivative method: response to hypoglycemia and upright posture (1974) (0)
- COMMENT ON CONSISTENCY. REPLY (1993) (0)
- Impact of Severe Hypoglycemia on Health-Related Quality of Life (HRQoL) in Insulin-Treated Patients with Type 1 and Type 2 Diabetes (2013) (0)
- Glucagon-stimulable Adenylyl Cyclase in Rat Liver of Streptozotocin-induced (0)
- REGRESSION OF ATHEROSCLEROSIS? (1976) (0)
- Introduction (2002) (0)
- AACE Response to viewpoint of December 9, 2013. (2014) (0)
- AACE/ACE Guidelines (2014) (0)
- Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52Weeks inMetformin-Treated PatientsWith Type 2 Diabetes A randomized, open-label trial (2012) (0)
- LETTER TO THE EDITOR. (2019) (0)
- New advances in insulin treatment of diabetes: overcoming barriers. (1997) (0)
- Focus on Incretin-Based Therapies for Patients with Type 2 Diabetes and Cardiovascular Disease (2011) (0)
- What is the best approach to glycaemic control in patients with type 2 diabetes? (2015) (0)
- SYNTHESIS, PURIFICATION BY HPLC AND ChARACTEKIZHTlON OE (1983) (0)
- Type 2 diabetes mellitus (2004) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Alan J. Garber?
Alan J. Garber is affiliated with the following schools:
